Loading...
Novartis AG
NVS•NYSE
Healthcare
Drug Manufacturers - General
$117.70
$0.24(0.20%)
Novartis AG (NVS) AI-Powered Stock Analysis
See how Novartis AG scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerNovartis AG (NVS) Stock Overall Grade
Novartis AG’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
A
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to Novartis AG's overall stock rating.
Forecast
A+Score
100/100Financial Growth
A+Score
90/100Fundamental Growth
AScore
86/100Key Ratios
A+Score
91/100Sector Comparison
B+Score
75/100Industry Comparison
A+Score
90/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
50/100Novartis AG (NVS) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 100/100 (A+), reflecting high confidence in its potential. Financial Growth (90/100, A+) and Fundamental Growth (86/100, A) highlight its stability, while Key Ratios (91/100, A+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Novartis AG stock grade, including financials, comparisons, and forecasts.